 |
|
|
|
 |
|
|
| Article 1 to 10 out of 18 concerning National Cancer Institute (NCI)
|
-
Bavarian Nordic announces partnership with National Cancer Institute in the US and obtains rights to a new vaccine candidate
(08/14/2008)
Bavarian Nordic's US subsidiary, BN ImmunoTherapeutics has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and Bavarian ...
-
Domestic cat genome sequenced
(11/01/2007)
A report that appears in the scientific journal Genome Research details the first assembly, annotation, and comparative analysis of the domestic cat genome (Felis catus). The DNA of a 4-year-old Abyssinian cat named Cinnamon, whose well-documented ...
-
US National Cancer Institute to test seven novel cancer drugs from Clavis Pharma
(05/29/2007)
Clavis Pharma announced that the US National Cancer Institute has accepted seven new compounds from the company for testing under its Developmental Therapeutics Program. The drug candidates, which are structurally novel analogues of several cancer ...
-
U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN
(05/16/2007)
Oncolytics Biotech Inc. announced that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of ...
-
TopoTarget and CuraGen Initiate NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer
(11/16/2006)
TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II clinical trial evaluating the antitumor activity of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of ...
-
Southwest Oncology Group Opens New Lymphoma Trial with CuraGen's and TopoTarget's PXD101
(08/28/2006)
CuraGen Corporation and TopoTarget A/S announced the Southwest Oncology Group, a national clinical trials cooperative group, has just opened a Phase II clinical trial to test the effects of a new investigational agent on aggressive B-cell lymphoma. ...
-
CuraGen and TopoTarget Initiate NCI-sponsored Phase I Clinical Trial of PXD101 and Azacitidine
(08/10/2006)
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with azacitidine ...
-
Cytogen Announces Initiation of Phase III Study Involving QUADRAMET(R)
(07/28/2006)
Cytogen Corporation announced that the National Cancer Institute's (NCI) Radiation Treatment Oncology Group (RTOG) has initiated a randomized phase III trial to evaluate either QUADRAMET (samarium Sm-153 lexidronam injection) or strontium-89 ...
-
Transgene to Collaborate in a Novel Melanoma Treatment Under a Cooperative Research and Development Agreement
(06/22/2006)
Transgene S.A. announced that it has executed a Cooperative Research and Development Agreement (CRADA) Letter of Intent with the National Cancer Institute (NCI) for the development of novel melanoma treatments with Steven A. Rosenberg, M.D., Ph.D., ...
-
Nventa announces positive HspE7 data from NCI-sponsored clinical trial in HIV-positive patients
(06/19/2006)
First Clinical Evidence that HspE7 May Have Activity in Immunocompromised Patients
Nventa Biopharmaceuticals Corporation announced results, recently published in the journal AIDS, from a clinical trial to test HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, on patients with high-grade ...
|
|
|
|
|
Top
